drugset / Trial / NCT00456898
Study Evaluating the Potential of DVS SR to Inhibit the CYP2D6 Pathway
RandomizedCrossoverOpen-labelTreatment
Summary
To evaluate the effects of multiple oral doses of desvenlafaxine sustained release (DVS SR) and paroxetine on the biotransformation of codeine to morphine in healthy subjects. To assess the safety and tolerability of DVS SR and paroxetine when coadministered with codeine to healthy subjects.
Timeline
- Start
- 2007-01
- Primary completion
- —
- Completion
- 2007-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Codeine | Small molecule | 60 mg | — |
| Subject | Desvenlafaxine | Other / unclassified | 100 mg | Oral |
| Subject | Paroxetine | Small molecule | 20 mg | Oral |